InvestSMART

Immuron Limited (ASX: IMC) - Announcements

- Current share price for IMC : $0.046

ASX company news and announcements for Immuron Limited (IMC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immuron Limited (IMC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immuron Limited (IMC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immuron Limited (IMC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$15 Immuron Appoints New Chief Executive Officer 25 Aug 2015 10:01AM $0.465 $0.046 fallen by 90.11%
$15 Immuron Commences US Investor Roadshow Presentation 19 Aug 2015 11:44AM $0.295 $0.046 fallen by 84.41%
$15 Shareholder Newsletter - August 2015 18 Aug 2015 11:36AM $0.285 $0.046 fallen by 83.86%
$15 Proposed Issue of Unlisted Options 6 Aug 2015 10:23AM $0.290 $0.046 fallen by 84.14%
$15 Immuron Executes Major US Travelan Sales Agreement 4 Aug 2015 11:11AM $0.270 $0.046 fallen by 82.96%
$15 Immuron Appoints Chief Operating & Scientific Officer 28 Jul 2015 11:06AM $0.240 $0.046 fallen by 80.83%
$15 Resignation of Chief Executive Officer 8 Jul 2015 9:41AM $0.230 $0.046 fallen by 80%
$15 NASH Clinical Trial Update - Patient Recruitment Advances 2 Jul 2015 10:21AM $0.250 $0.046 fallen by 81.60%
$15 Appendix 3Y - Change of Director's Interest Notice (DP) 23 Jun 2015 6:19PM $0.230 $0.046 fallen by 80%
$15 Immuron Appoints Senior Vice President of Innovation 11 Jun 2015 9:50AM $0.220 $0.046 fallen by 79.09%
$15 Appendix 3Y - Change of Director's Interest Notice (PA) 27 May 2015 9:57AM $0.210 $0.046 fallen by 78.10%
$15 Appendix 3X - Initial Director's Interest Notice (PA) 21 May 2015 5:27PM $0.210 $0.046 fallen by 78.10%
$15 Immuron Appoints New Director - Mr Peter Anastasiou 21 May 2015 9:59AM $0.210 $0.046 fallen by 78.10%
$15 IMMURON ANNOUNCES FIRST USA ORDERS FOR TRAVELAN 20 Apr 2015 1:10PM $0.190 $0.046 fallen by 75.79%
$15 Immuron Appoints Dr. Leearne Hinch as New CEO 2 Apr 2015 9:47AM $0.160 $0.046 fallen by 71.25%
$15 Appendix 4D - Half Yearly Report and Accounts 18 Feb 2015 11:44AM n/a $0.046 n/a
$15 Marketing and Distribution Agreement signed for China 17 Feb 2015 9:29AM $0.215 $0.046 fallen by 78.60%
$15 Patient Recruitment Commenced for Phase 2 NASH Trial 3 Feb 2015 1:45PM n/a $0.046 n/a
$15 IMC signs License Agreement for Development for Alcohol Tox 6 Jan 2015 12:04PM $0.200 $0.046 fallen by 77%
$15 Resignation of CEO 18 Dec 2014 10:43AM $0.210 $0.046 fallen by 78.10%
$15 Immuron Completes Capital Consolidation 20 Nov 2014 2:27PM $0.240 $0.046 fallen by 80.83%
$15 NASH & ASH Clinical Trial Update 15 Oct 2014 9:24AM $0.007 $0.046 risen by 557.14%
$15 Immuron Improves Hadasit Royalty Terms 2 Sep 2014 10:01AM $0.007 $0.046 risen by 557.14%
$15 Appendix 4E Preliminary Final Report and Statutory Accounts 29 Aug 2014 3:51PM $0.006 $0.046 risen by 666.67%
$15 Paladin Labs Announces the Launch of Travelan in Canada 6 Aug 2014 9:39AM $0.005 $0.046 risen by 820%

676 - 700 of 782 results

Page 28 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.